U.S. Health and Human Services Secretary Robert F. Kennedy Jr. plans to require all new vaccines be tested against a placebo ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated.

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized ...

(Reuters) -Infant hospitalizations due to respiratory syncytial virus (RSV) infections in the United States dropped as much ...

The overall uptake of RSV vaccine is low during its first season in those aged 60 years or older in the United States. The ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.